RBC Capital downgraded Aurinia Pharmaceuticals (AUPH) to Sector Perform from Outperform with a price target of $15, up from $9. The firm says the shares have doubled over the last 12 months due to stronger than expected Lupkynis sales and improved operating leverage. RBC no longer believes the shares “carry an asymmetric risk/reward outlook.” It wants more clarity on aritinercept’s future development path before again recommending the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUPH:
- Promising Sales and Market Potential of Lupkynis Drive Buy Rating for Aurinia Pharmaceuticals
- Aurinia Pharmaceuticals Boosts 2025 Sales Guidance Amid Strong Q3 Performance
- Aurinia Pharmaceuticals Reports Strong Q3 2025 Growth and Raises Sales Guidance
- Aurinia Pharmaceuticals reports Q3 EPS 23c, consensus 16c
- Aurinia Pharmaceuticals raises FY25 revenue view to $275M-$280M from $260M-$270M